Abstract | INTRODUCTION:
Diabetes mellitus impacts almost 200 million individuals worldwide and leads to debilitating complications. New avenues of drug discovery must target the underlying cellular processes of oxidative stress, apoptosis, autophagy, and inflammation that can mediate multi-system pathology during diabetes mellitus. AREAS COVERED: EXPERT OPINION:
Nicotinamide, erythropoietin, and the downstream pathways of SIRT1, mTOR, forkhead transcription factors, and wingless signaling offer exciting prospects for novel directions of drug discovery for the treatment of metabolic disorders. Future investigations must dissect the complex relationship and fine modulation of these pathways for the successful translation of robust reparative and regenerative strategies against diabetes mellitus and the complications of this disorder.
|
Authors | Kenneth Maiese, Zhao Zhong Chong, Yan Chen Shang, Shaohui Wang |
Journal | Expert opinion on drug discovery
(Expert Opin Drug Discov)
Vol. 8
Issue 1
Pg. 35-48
(Jan 2013)
ISSN: 1746-045X [Electronic] England |
PMID | 23092114
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Hypoglycemic Agents
- Erythropoietin
- Niacinamide
- MTOR protein, human
- TOR Serine-Threonine Kinases
|
Topics |
- Animals
- Diabetes Mellitus
(drug therapy, metabolism)
- Drug Delivery Systems
(methods, trends)
- Drug Discovery
(methods, trends)
- Erythropoietin
(administration & dosage, metabolism)
- Humans
- Hypoglycemic Agents
(administration & dosage, metabolism)
- Niacinamide
(administration & dosage, metabolism)
- Signal Transduction
(drug effects, physiology)
- TOR Serine-Threonine Kinases
(metabolism)
|